ATE181912T1 - Antivirale tetrahydropyrane - Google Patents

Antivirale tetrahydropyrane

Info

Publication number
ATE181912T1
ATE181912T1 AT94100982T AT94100982T ATE181912T1 AT E181912 T1 ATE181912 T1 AT E181912T1 AT 94100982 T AT94100982 T AT 94100982T AT 94100982 T AT94100982 T AT 94100982T AT E181912 T1 ATE181912 T1 AT E181912T1
Authority
AT
Austria
Prior art keywords
alkyl
tetrahydropyrans
substd
aryl
opt
Prior art date
Application number
AT94100982T
Other languages
English (en)
Inventor
Joseph A Tino
Gregory S Bisacchi
Saleem Ahmad
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE181912T1 publication Critical patent/ATE181912T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT94100982T 1993-01-25 1994-01-24 Antivirale tetrahydropyrane ATE181912T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/009,485 US5314893A (en) 1993-01-25 1993-01-25 Antiviral tetrahydropyrans

Publications (1)

Publication Number Publication Date
ATE181912T1 true ATE181912T1 (de) 1999-07-15

Family

ID=21737951

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94100982T ATE181912T1 (de) 1993-01-25 1994-01-24 Antivirale tetrahydropyrane

Country Status (10)

Country Link
US (3) US5314893A (de)
EP (1) EP0608809B1 (de)
JP (1) JPH06271574A (de)
AT (1) ATE181912T1 (de)
AU (1) AU672845B2 (de)
CA (1) CA2111549A1 (de)
DE (1) DE69419328T2 (de)
DK (1) DK0608809T3 (de)
ES (1) ES2133423T3 (de)
GR (1) GR3031404T3 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874578A (en) * 1992-07-13 1999-02-23 Bristol-Myers Squibb Process for preparing guanine-containing antiviral agents and purinyl salts useful in such process
JPH06263793A (ja) * 1993-03-04 1994-09-20 Asahi Breweries Ltd ピラノース型ヌクレオシド誘導体
JP2000505778A (ja) * 1994-08-17 2000-05-16 スティヒティング・レガ・ヴェー・ゼット・ウェー 核酸に関する配列特異的結合性オリゴマーおよびアンチセンスストラテジーにおけるそれらの用途
EP0784624A1 (de) * 1994-10-05 1997-07-23 Chiroscience Limited Purin und guaninderivate als pnp inhibitoren
KR960031456A (ko) * 1995-02-07 1996-09-17 김충환 새로운 테트라하이드로피란 유도체 및 그 제조방법
US5659023A (en) * 1995-02-01 1997-08-19 Gilead Sciences, Inc. Nucleotide analogues
WO1997030064A1 (en) * 1996-02-16 1997-08-21 Stichting Rega Vzw Hexitol containing oligonucleotides and their use in antisense strategies
CA2463719A1 (en) * 2003-04-05 2004-10-05 F. Hoffmann-La Roche Ag Nucleotide analogs with six membered rings
JP5572090B2 (ja) 2007-08-15 2014-08-13 アイシス ファーマシューティカルズ， インコーポレーテッド テトラヒドロピラン核酸類似体
US8530640B2 (en) * 2008-02-07 2013-09-10 Isis Pharmaceuticals, Inc. Bicyclic cyclohexitol nucleic acid analogs
WO2010090969A1 (en) 2009-02-06 2010-08-12 Isis Pharmaceuticals, Inc. Tetrahydropyran nucleic acid analogs
US20120021515A1 (en) 2009-02-06 2012-01-26 Swayze Eric E Oligomeric compounds and methods
JP6005628B2 (ja) 2010-04-28 2016-10-12 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 修飾ヌクレオシド、その類似体、およびこれらから調製されるオリゴマー化合物
EP3647318B1 (de) 2014-04-28 2021-06-30 Ionis Pharmaceuticals, Inc. Verbindungsmodifizierte oligomerverbindungen
TW202042822A (zh) 2019-01-22 2020-12-01 美商科羅生物公司 Rna編輯之寡核苷酸及其用途
CN113518623A (zh) 2019-01-22 2021-10-19 科罗生物公司 Rna编辑的寡核苷酸及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3002965A (en) * 1958-04-17 1961-10-03 Hoffmann La Roche Nucleosides and their preparation
JPS52128395A (en) * 1976-04-19 1977-10-27 Takeda Chem Ind Ltd Aristeromycin derivatives
AU610344B2 (en) * 1988-02-29 1991-05-16 Taiho Pharmaceutical Co., Ltd. 2'-deoxy-5-fluorouridine derivatives
GB2218417B (en) * 1988-04-21 1991-09-18 Central Glass Co Ltd Preparation of 2'-deoxy-5,6-dihydro-5-fluoro-6-hydroxy uridine and diaryl 2'- deoxy-5-fluorouridines
JPH01296841A (ja) * 1988-05-25 1989-11-30 Nec Corp 電話機
US5059690A (en) * 1990-03-01 1991-10-22 E. R. Squibb & Sons, Inc. Purinyl tetrahydrofurans
ZA914894B (en) * 1990-07-02 1992-04-29 Squibb & Sons Inc Purinyl and pyrimidinyl tetrahydrofurans
US5374625A (en) * 1990-07-24 1994-12-20 Nippon Kayaku Kabushiki Kaisha Adenine and guanine derivatives for the treatment of hepatitis virus infections

Also Published As

Publication number Publication date
DK0608809T3 (da) 1999-11-22
DE69419328D1 (de) 1999-08-12
US5414000A (en) 1995-05-09
CA2111549A1 (en) 1994-07-26
AU672845B2 (en) 1996-10-17
GR3031404T3 (en) 2000-01-31
EP0608809A1 (de) 1994-08-03
ES2133423T3 (es) 1999-09-16
DE69419328T2 (de) 2000-03-30
US5314893A (en) 1994-05-24
EP0608809B1 (de) 1999-07-07
JPH06271574A (ja) 1994-09-27
AU5394694A (en) 1994-07-28
US5414096A (en) 1995-05-09

Similar Documents

Publication Publication Date Title
DE69419328D1 (de) Antivirale Tetrahydropyrane
DE69321285D1 (de) Äusserliches Hautpräparat
DE59402610D1 (en) Ortho-substituierte 2-methoxyiminophenylessigsäuremethylamide
DE3585781D1 (de) Verwendung von thiophenverbindungen zur herstellung von medikamenten gegen tumore.
ES2083479T3 (es) Bis(hidroximetil)ciclobutil-purinas y pirimidinas fluoradas.
HU9600517D0 (en) New tricyclic derivatives, their preparation, their use for the preparation of optically active or valemic colchicine and thiocolchine and analogues or derivatives and intermediates
NO963374D0 (no) Substituerte 4H-pyraner
DK0620857T3 (da) Syntese af homochirale 2-hydroxysyrer
DK0722934T3 (da) Fremgangsmåde til fremstilling af i 5-stillingen substituerede 2-chlorpyridiner
CO5011022A1 (es) Intermediarios arino y un proceso para la preparacion de estos
FI933468A0 (fi) Tetrahydronaftalenderivat, framstaellning av dessa och terapeutisk anvaendning av dessa
DK0645374T3 (da) 5-Amino-2-phenoxylsulfonanilidforbindelse
GR3035097T3 (en) Acyl substituted aminopyrans with a modulating effect on calcium channels
ES8704179A1 (es) Procedimiento de preparacion de analogos de la estefimicinona
SU1641159A1 (ru) Активная среда лазера с ламповой накачкой

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee